Tags

Type your tag names separated by a space and hit enter

Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
J Am Acad Child Adolesc Psychiatry. 2005 Mar; 44(3):240-8.JA

Abstract

OBJECTIVE

To examine (1) moderating effects of oppositional defiant disorder (ODD) on attention-deficit/hyperactivity disorder (ADHD) treatment response and (2) responses of ODD symptoms to atomoxetine.

METHOD

Children and adolescents (ages 8-18) with ADHD were treated for approximately 8 weeks with placebo or atomoxetine (fixed dosing: 0.5, 1.2, or 1.8 mg/kg/day, b.i.d.) under randomized, double-blind conditions. Among patients with lifetime diagnostic information (n = 293), 39% were diagnosed with comorbid ODD and 61% were not. Treatment-group differences and differences between patients with and without comorbid ODD were examined post hoc for changes on the Attention-Deficit/Hyperactivity Disorder Rating Scale IV-Parent version, investigator-administered and -scored; Conners' Parent Rating Scale-Revised Short Form; Clinical Global Impressions Severity of ADHD Scale; and the parent-rated Child Health Questionnaire.

RESULTS

Youths with ADHD and comorbid ODD showed statistically significant improvement in ADHD, ODD, and quality-of-life measures. Treatment response was similar in youths with and without ODD, except that the comorbid group showed improvement compared with placebo at 1.8 mg/kg/day but not 1.2 mg/kg/day. In contrast, youths without ODD showed improvement at 1.2 mg/kg/day and no incremental benefit at 1.8 mg/kg/day.

CONCLUSIONS

Atomoxetine treatment improves ADHD and ODD symptoms in youths with ADHD and ODD, although the comorbid group may require higher doses.

Authors+Show Affiliations

Department of Psychiatry, Mount Sinai School of Medicine, New York 10029, USA. jeffrey.newcorn@mssm.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15725968

Citation

Newcorn, Jeffrey H., et al. "Atomoxetine Treatment in Children and Adolescents With Attention-deficit/hyperactivity Disorder and Comorbid Oppositional Defiant Disorder." Journal of the American Academy of Child and Adolescent Psychiatry, vol. 44, no. 3, 2005, pp. 240-8.
Newcorn JH, Spencer TJ, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):240-8.
Newcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R., & Michelson, D. (2005). Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 44(3), 240-8.
Newcorn JH, et al. Atomoxetine Treatment in Children and Adolescents With Attention-deficit/hyperactivity Disorder and Comorbid Oppositional Defiant Disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):240-8. PubMed PMID: 15725968.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. AU - Newcorn,Jeffrey H, AU - Spencer,Thomas J, AU - Biederman,Joseph, AU - Milton,Denái R, AU - Michelson,David, PY - 2005/2/24/pubmed PY - 2005/5/4/medline PY - 2005/2/24/entrez SP - 240 EP - 8 JF - Journal of the American Academy of Child and Adolescent Psychiatry JO - J Am Acad Child Adolesc Psychiatry VL - 44 IS - 3 N2 - OBJECTIVE: To examine (1) moderating effects of oppositional defiant disorder (ODD) on attention-deficit/hyperactivity disorder (ADHD) treatment response and (2) responses of ODD symptoms to atomoxetine. METHOD: Children and adolescents (ages 8-18) with ADHD were treated for approximately 8 weeks with placebo or atomoxetine (fixed dosing: 0.5, 1.2, or 1.8 mg/kg/day, b.i.d.) under randomized, double-blind conditions. Among patients with lifetime diagnostic information (n = 293), 39% were diagnosed with comorbid ODD and 61% were not. Treatment-group differences and differences between patients with and without comorbid ODD were examined post hoc for changes on the Attention-Deficit/Hyperactivity Disorder Rating Scale IV-Parent version, investigator-administered and -scored; Conners' Parent Rating Scale-Revised Short Form; Clinical Global Impressions Severity of ADHD Scale; and the parent-rated Child Health Questionnaire. RESULTS: Youths with ADHD and comorbid ODD showed statistically significant improvement in ADHD, ODD, and quality-of-life measures. Treatment response was similar in youths with and without ODD, except that the comorbid group showed improvement compared with placebo at 1.8 mg/kg/day but not 1.2 mg/kg/day. In contrast, youths without ODD showed improvement at 1.2 mg/kg/day and no incremental benefit at 1.8 mg/kg/day. CONCLUSIONS: Atomoxetine treatment improves ADHD and ODD symptoms in youths with ADHD and ODD, although the comorbid group may require higher doses. SN - 0890-8567 UR - https://www.unboundmedicine.com/medline/citation/15725968/Atomoxetine_treatment_in_children_and_adolescents_with_attention_deficit/hyperactivity_disorder_and_comorbid_oppositional_defiant_disorder_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0890-8567(09)61469-6 DB - PRIME DP - Unbound Medicine ER -